Noxopharm (ASX:NOX) has announced the publication in an abstract form of the latest survival data from the LuPIN study ahead of a formal presentation to the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.
“This data has been generated in an independent study and is being shared on the world stage by leading Australian researchers," said Noxopharm CEO Dr Graham Kelly.
"The reported median overall survival outcome of 19.7 months means that at least half of men who have progressive end-stage prostate cancer, and who have come to the end of their treatment journey, are being offered at least another 20 months of life.
"This is an extraordinary outcome and easily exceeds that obtained with any of the current treatments for Stage 4 prostate cancer in their registration studies. That difference is even more remarkable when you consider that those other treatments were tested in men with considerably less advanced disease than those in the LuPIN study.”
Dr Kelly continued, “Today’s clinical data continues to cement the view that Veyonda (NOX66) is on track to become a major new immunotherapy oncology drug of medical and commercial significance. The DARRT program has already suggested this and the LuPIN program now confirms it. All of which augurs well for our upcoming IONIC program. Collectively, these three programs highlight the diversity of use and potential value of Veyonda."
The LuPIN study enrolled a total of 56 patients with metastatic castration-resistant prostate cancer (mCRPC) whose cancer had progressed on all three standard lines of therapy for late-stage disease. They were treated with Veyonda in combination with Lu-PSMA-617.
Noxopharm said these men were regarded as having reached the "end of their treatment journey."
"The goal of the combined (LuPIN) treatment was to slow or to block tumour progression in order to deliver a better quality of life and extended survival and to do so in a well-tolerated way," it said.
The median Overall Survival (mOS) for the 56 men in the LuPIN study was 19.7 months. This is an increase on the 17.1 months reported 12 months ago (at the same conference for the first 32 men in the study. mOS is a standard measure of efficacy in cancer studies and is the time at which half the patients remain alive and half are deceased.
The company said the 19.7-month survival benefit compares to 4.5 months reported in a study in men with Stage 4 mCRPC whose disease had progressed on standard therapies. It said, in terms of how much Veyonda is contributing to the combined drug effect, 19.7 months compares to 13.3 months reported in an Australian study where 177Lu-PSMA-617 was used on its own.